Ensuring safer and effective pharmaceutical formulations by X-ray diffraction

X-ray Diffraction in Pharmaceutical Analysis: Ensuring Safer and More Effective Formulations

Importance of the topic

X-ray diffraction (XRD) is a cornerstone analytical technique across the pharmaceutical lifecycle, from early discovery and preformulation work to process development, manufacturing and final QA/QC release. Its ability to deliver phase-specific structural fingerprints and to quantify crystalline versus amorphous content makes XRD essential for addressing polymorphism, salt selection, crystallinity-driven bioavailability, and stability concerns. The method’s nondestructive nature and suitability for small samples further enhance its value when material is scarce or precious.

Objectives and study overview

The source document presents the role and practical benefits of benchtop XRD—specifically the Thermo Scientific ARL EQUINOX 100 platform and SolstiX software—in pharmaceutical applications. It emphasizes in-situ/real-time and transmission XRD for monitoring phase transitions and reactivity/stability under controlled environments, outlines top application areas, and highlights regulatory-ready software features to support 21 CFR Part 11 compliance in regulated laboratories.

Methodology and instrumentation

XRD experiments described include full-pattern, real-time powder diffraction in both reflection and transmission geometries. The methodology supports rapid screening of formulations, polymorph and salt screening, quantitative phase analysis, crystallinity estimation, crystallite size evaluation, and monitoring of induced structural changes. Instruments accommodate diverse sample formats (powders, tablets, small-volume capillaries) and allow controlled-environment experiments for stability/reactivity studies.

Used instrumentation

The key instrument and software elements highlighted are listed below:

• Thermo Scientific ARL EQUINOX 100 benchtop X-ray diffractometer: compact footprint for laboratory and near-line use, dual-mode (reflection and transmission).
• Real-time position-sensitive detector (PSD) technology enabling full-pattern, rapid acquisition.
• Micro-focus X-ray source with air-cooling (no external water cooling required).
• Accessory options: sample spinner, capillary stage, automated sample changer, and controlled-environment/sample chambers for in-situ studies.
• Thermo Scientific SolstiX XRD Software with Security Suite: features to support electronic record protection, authentication, audit trails and electronic signatures for 21 CFR Part 11 compliance.

Main results and discussion

The document synthesizes practical advantages of using a benchtop XRD workflow for pharmaceutical development and control. Key points include:

• High sensitivity to crystalline phases provides unambiguous phase identification and fingerprinting suitable for polymorph screening, counterfeit detection and formulation comparisons.
• Real-time XRD enables observation of phase transitions, reaction intermediates and stability-related changes under controlled temperature, humidity or chemical environments, which is critical for preformulation and process optimization.
• Transmission mode is particularly advantageous for organic APIs and when only very small sample quantities are available, preserving scarce material while delivering interpretable diffraction information.
• Quantitative phase analysis and crystallinity estimation support assessments of bioavailability, manufacturability and batch-to-batch consistency.
• Software security and data integrity capabilities address regulatory needs by ensuring records are authentic, timestamped, and traceable.

Limitations and practical considerations are noted: diffraction is inherently less sensitive to amorphous content than crystalline phases and benefits from complementary techniques (e.g., DSC, Raman, solid-state NMR, infrared spectroscopy) for full solid-state characterization. Sample preparation, preferred orientation, particle size effects and detection limits for minor phases must be managed through method design and calibration.

Benefits and practical applications

Practical advantages of applying XRD in pharmaceutical settings include:

• Rapid screening of polymorphs and salts to de-risk formulation development.
• Non-destructive verification of identity and phase purity for QA/QC release and forensic screening of suspected counterfeit products.
• Process control and PAT-enabled monitoring of solid-state transformations during manufacturing and scale-up.
• Small-sample capability to support early discovery or limited-availability APIs.
• Uniform methodology across R&D and production labs enabling consistent libraries and comparability of results.

Future trends and potential applications

Emerging directions that will expand XRD utility in pharma include:

• Deeper integration with Process Analytical Technology (PAT) for inline or at-line monitoring and real-time process control.
• Advanced in-situ cells and environmental stages enabling multi-parameter stress testing (temperature, humidity, solvent vapor) during diffraction experiments.
• Application of machine learning for automated phase recognition, quantification in complex mixtures, and predictive modeling of polymorph stability.
• Higher-throughput benchtop systems and improved detector technology to shorten cycle times for screening and QC.
• Tighter regulatory automation with secure data handling, audit trails and electronic-signature workflows to streamline validation and compliance.

Conclusion

X-ray diffraction remains a gold-standard structural technique for pharmaceutical solid-state characterization. Modern benchtop XRD systems combining rapid full-pattern acquisition, dual-mode sample handling and regulatory-ready software permit deployment from discovery through manufacturing and QA/QC. While XRD excels at identifying and quantifying crystalline phases, optimal solid-state characterization typically couples XRD with complementary thermal and spectroscopic methods. Ongoing advances in detectors, in-situ capabilities and data analytics will further enhance XRD’s role in ensuring product quality, safety and effective scale-up.

Reference

Thermo Fisher Scientific. Product and application summary for Thermo Scientific SolstiX XRD Software and ARL EQUINOX 100 benchtop diffractometer, 2023.